Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
THANK YOU FOR SUBSCRIBING
Visiopharm: Redefining Precision Medicine through AI
Dirk Vossen, Chief Diagnostic Officer, Visiopharm
Similar to how medical imaging technologies such as X-rays and MRIs transformed the healthcare landscape in the 1900s, the application of artificial intelligence (AI) in data analysis and sample testing has revolutionized the industry in the 21st century. This is evident in precision medicine, especially oncology, which has always been a tricky space for biopharmaceutical companies and pathology labs due to a lack of accurate research data analysis and test subject identification. AI has offered a way out of this predicament by seemingly launching endless tools for each discrete genre of precision medicine. However, with more tools come more data, and subsequently, an unnecessary churn for the users in interpreting the data. For instance, therapies involved in immuno-oncology demand for accurate identification of test subjects that can respond to the treatment. This identification is done using biomarkers that are notoriously complex and non-standardized; machine learning, on the other hand, has changed this notion. Denmark-based Visiopharm substantiates this hypothesis through its mastery over AI-based image analysis and workflow standardization. Visiopharm, a global leader in providing AI-driven pathology software, has been a driving force in improving clinical workflows and research initiatives.
Leveraging its thorough understanding of AI and ML, the company provides state-of-the-art, specialized tools for comprehensive interpretation and analysis of research data. Its 20 years of experience in image analysis of stained tissue sections and bolstering data mining modalities have been integral to providing flexible and powerful tools for researchers and pathologists.
“Building upon research competencies, Visiopharm employs its AI-powered tools in the field of diagnostics to further the vision of supporting patients, clinicians, and pathologists,” says Dirk Vossen, Chief Diagnostic Officer of the company.
The company is built on two sturdy pillars - on AI and its applicability for image analysis of tissues. “To assist the researchers in developing precision medicines, we utilize tissue imaging functionalities and AI-driven tools to elucidate and analyze data,” adds Vossen. In addition to ready-to-use AI-based APPs, Visiopharm additionally offers a unique AI platform that enables researchers to develop applications themselves as per their requirements. “You don’t need a PhD in artificial intelligence for image analysis. The algorithms are highly simplistic and intuitive, allowing you to build your own solutions and manage data while facilitating the needed scalability,” adds the Chief Diagnostic Officer. Moreover, the applications developed by researchers can also be shared with other users in different sites through this platform.
An instance that sheds light on Visiohpharm’s unique value proposition, is the company’s collaboration with Biopharma and diagnostic reagent manufacturers. In a recent partnership, Visiopharm assisted a diagnostic company which had launched a new assay. Visiopharm worked with their client to develop an application which could accurately interpret the assay digitally. It not only improved the quality of research and reduced the variation in interpretation but also provided a strong foundation for the client to highlight their products.
Visiopharm aims to standardize quality management and reduce variations in data interpretation through AI.
Another instance that exemplifies the significance of Visiopharm’s AI-based diagnostic solutions is the company’s engagement with the Danish healthcare system that was looking to transform pathology workflows digitally. Upon comprehension of the requirement, Visiopharm integrated AI to its workflows and enabled the client to apply AI for breast cancer use cases.
Building upon such successful collaborations and further enhancing precision medicines, Visiopharm aims to standardize quality management and reduce variations in data interpretation through AI. The company will also continue to assist the researchers through its offerings and help them achieve their deliverables. Collectively, Visiopharm redefines precision medicine by infusing an element of AI in healthcare workflows.
Description Visiopharm is a worl+B7:E11d leader in AI-based image analysis and workflow standardization solutions for digital pathology. Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows. Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses in more than 38 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in London, England, Munich, Germany, and Westminster, Colorado
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: